Intra-tumoral heterogeneity of HER2, FGFR2, cMET and ATM in gastric cancer: Optimizing personalized healthcare through innovative pathological and statistical analysis

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Ye, Peng ^a   Zhang, Meizhuo ^a   Fan, Shuqiong ^a   Zhang, Tianwei ^a   Fu, Haihua ^a   Su, Xinying ^a   Gavine, Paul R ^a   Liu, Qiang ^b   Yin, Xiaolu ^a  

^a ASTRAZENECA   (United Kingdom)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; SCATTER FACTOR RECEPTOR; TUMOR MARKER; ATM PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; MET PROTEIN, HUMAN;

ARTICLE; CELL HETEROGENEITY; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; CONTROLLED STUDY; FALSE NEGATIVE RESULT; HEALTH CARE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATHOLOGY; PERSONALIZED MEDICINE; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL ANALYSIS; STOMACH CANCER; TUMOR BIOPSY; BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; PROCEDURES; STOMACH NEOPLASMS;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; BIOMARKERS, TUMOR; BIOPSY; FALSE NEGATIVE REACTIONS; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PRECISION MEDICINE; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RISK ASSESSMENT; STOMACH NEOPLASMS;

EID: 84957991275     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143207     Document Type: Article

References (29)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359-386. doi: 10.1002/ijc.29210 PMID: 25220842
2. Pourhoseingholi MA, Vahedi M, Baghestani AR. Burden of gastrointestinal cancer in Asia; an overview. Gastroenterol Hepatol Bed Bench. 2015; 8:19-27. PMID: 25584172
3. Power DG, Kelsen DP, Shah MA. Advanced gastric cancer-slow but steady progress. Cancer Treat Rev. 2010; 36:384-392. doi: 10.1016/j.ctrv.2010.01.005 PMID: 20176443
4. de Aretxabala X, Yonemura Y, Sugiyama K, Hirose N, Kumaki T, Fushida S, et al. Gastric cancer heterogeneity. Cancer. 1989; 63:791-798. PMID: 2914285
5. Yonemura Y, Matsumoto H, Ninomiya I, Ohoyama S, Kimura H, de Aletxabala X, et al. Heterogeneity of DNA ploidy in gastric cancer. Anal Cell Pathol. 1992; 4:61-67. PMID: 1550795
6. Yang J, Luo H, Li Y, Li J, Cai Z, Su X, et al. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys. 2012; 62:221-228. doi: 10.1007/s12013-011-9286-1 PMID: 21927816
7. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer. 2010; 103:1139-1143. doi: 10.1038/sj.bjc.6605912 PMID: 20877357
8. McGranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C. Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep. 2012; 13:528-538. doi: 10.1038/embor.2012.61 PMID: 22595889
9. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010; 146:264-275. doi: 10.1016/j.jconrel.2010.04.009 PMID: 20385184
10. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376:687-697. doi: 10.1016/S0140-6736(10)61121-X PMID: 20728210
11. Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK, et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene. 1991; 6:501-504. PMID: 1827664
12. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12:89-103. doi: 10.1038/nrc3205 PMID: 22270953
13. Gavine PR, Ren Y, Han L, Lv J, Fan S, Zhang W, et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patientderived tumor xenograft models. Mol Oncol. 2015; 9:323-333. doi: 10.1016/j.molonc.2014.08.015 PMID: 25248999
14. Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res. 2013; 19:2572-2583. doi: 10.1158/1078-0432.CCR-12-3898 PMID: 23493349
15. Lee J, Ou SH. Towards the goal of personalized medicine in gastric cancer-time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway. Discov Med. 2013; 16:7-14. PMID: 23911227
16. Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X, et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer. 2014; 110:967-975. doi: 10.1038/bjc.2013.802 PMID: 24457912
17. Lee JH, Paull TT. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene. 2007; 26:7741-7748. PMID: 18066086
18. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003; 3:155-168. PMID: 12612651
19. Inskip HM, Kinlen LJ, Taylor AM, Woods CG, Arlett CF. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br J Cancer. 1999; 79:1304-1307. PMID: 10098776
20. Ye Q, Chen L, Yin X, Liu YJ, Ji Q, Zhao E. Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins. Pathol Oncol Res. 2014; 20:931-938. doi: 10.1007/s12253-014-9776-8 PMID: 24752797
21. Gilardini Montani MS, Prodosmo A, Stagni V, Merli D, Monteonofrio L, Gatti V, et al. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J Exp Clin Cancer Res. 2013; 32:95. doi: 10.1186/1756-9966-32-95 PMID: 24252502
22. Kubota E, Williamson CT, Ye R, Elegbede A, Peterson L, Lees-Miller SP, et al. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle. 2014; 13:2129-2137. doi: 10.4161/cc.29212 PMID: 24841718
23. Guo XN, D.H. S, Cheng WX, Bai Y, Ni XZ, Shen DP, et al. ATM deficiency sensitizes gastric cancer cells to the PARP inhibitior olaparib. In: In Press Mol Cancer Ther 8(12 Suppl):B42, 2009.
24. Min A, Im SA, Yoon YK, Song SH, Nam HJ, Hur HS, et al. RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. Mol Cancer Ther. 2013; 12:865-877. doi: 10.1158/1535-7163. MCT-12-0950 PMID: 23512992
25. Reimers MS, Zeestraten EC, Kuppen PJ, Liefers GJ, van de Velde CJ. Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf). 2013; 1:166-183.
26. Liu YJ, Shen D, Yin X, Gavine P, Zhang T, Su X, et al. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. Br J Cancer. 2014; 110:1169-1178. doi: 10.1038/bjc.2014.61 PMID: 24518603
27. Feng Y, Ma PC. Anti-MET targeted therapy has come of age: the first durable complete response with Met MAb in metastatic gastric cancer. Cancer Discov. 2011; 1:550-554. doi: 10.1158/2159-8290.CD- 11-0289 PMID: 22586678
28. Cunningham D, Bang YJ, Tabemero J, Shah MA, Lordick F, Hack SP. Met Gastric: A randomized phase III study of onartuzumab (Met MAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction. In: In Press J Clin Oncol 31, 2013 (suppl; abstr TPS4155), 2013.
29. Kim HS, Kim MA, Hodgson D, Harbron C, Wellings R, O'Connor MJ, et al. Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients. Pathobiology. 2013; 80:127-137. doi: 10.1159/000346034 PMID: 23328638